S&P 500   3,104.75 (-0.49%)
DOW   27,790.31 (-0.51%)
QQQ   201.64 (-0.85%)
CGC   17.71 (+15.53%)
BABA   182.05 (-1.73%)
GE   11.37 (-1.13%)
T   37.01 (-2.61%)
ACB   2.61 (+11.54%)
DIS   146.49 (-1.27%)
S&P 500   3,104.75 (-0.49%)
DOW   27,790.31 (-0.51%)
QQQ   201.64 (-0.85%)
CGC   17.71 (+15.53%)
BABA   182.05 (-1.73%)
GE   11.37 (-1.13%)
T   37.01 (-2.61%)
ACB   2.61 (+11.54%)
DIS   146.49 (-1.27%)
S&P 500   3,104.75 (-0.49%)
DOW   27,790.31 (-0.51%)
QQQ   201.64 (-0.85%)
CGC   17.71 (+15.53%)
BABA   182.05 (-1.73%)
GE   11.37 (-1.13%)
T   37.01 (-2.61%)
ACB   2.61 (+11.54%)
DIS   146.49 (-1.27%)
S&P 500   3,104.75 (-0.49%)
DOW   27,790.31 (-0.51%)
QQQ   201.64 (-0.85%)
CGC   17.71 (+15.53%)
BABA   182.05 (-1.73%)
GE   11.37 (-1.13%)
T   37.01 (-2.61%)
ACB   2.61 (+11.54%)
DIS   146.49 (-1.27%)
Log in

Inovio Pharmaceuticals Stock Price, Forecast & Analysis (NASDAQ:INO)

$2.48
+0.11 (+4.64 %)
(As of 11/20/2019 03:21 PM ET)
Today's Range
$2.38
Now: $2.48
$2.49
50-Day Range
$1.97
MA: $2.27
$2.56
52-Week Range
$1.91
Now: $2.48
$5.47
Volume45,715 shs
Average Volume810,364 shs
Market Capitalization$248.02 million
P/E RatioN/A
Dividend YieldN/A
Beta2.05
Inovio Pharmaceuticals, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:INO
CUSIPN/A
Phone267-440-4200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$30.48 million
Book Value$0.91 per share

Profitability

Net Income$-96,970,000.00
Net Margins-1,809.64%

Miscellaneous

Employees281
Market Cap$248.02 million
Next Earnings Date3/10/2020 (Estimated)
OptionableOptionable

Receive INO News and Ratings via Email

Sign-up to receive the latest news and ratings for INO and its competitors with MarketBeat's FREE daily newsletter.


Inovio Pharmaceuticals (NASDAQ:INO) Frequently Asked Questions

What is Inovio Pharmaceuticals' stock symbol?

Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO."

When did Inovio Pharmaceuticals' stock split? How did Inovio Pharmaceuticals' stock split work?

Inovio Pharmaceuticals shares reverse split before market open on Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 5th 2014. An investor that had 100 shares of Inovio Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.

How were Inovio Pharmaceuticals' earnings last quarter?

Inovio Pharmaceuticals Inc (NASDAQ:INO) announced its earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, topping analysts' consensus estimates of ($0.26) by $0.01. The biopharmaceutical company had revenue of $0.87 million for the quarter, compared to the consensus estimate of $2.72 million. Inovio Pharmaceuticals had a negative net margin of 1,809.64% and a negative return on equity of 179.91%. During the same period last year, the company earned ($0.27) EPS. View Inovio Pharmaceuticals' Earnings History.

When is Inovio Pharmaceuticals' next earnings date?

Inovio Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Inovio Pharmaceuticals.

What price target have analysts set for INO?

5 brokers have issued 1-year target prices for Inovio Pharmaceuticals' shares. Their forecasts range from $3.62 to $13.00. On average, they expect Inovio Pharmaceuticals' stock price to reach $7.32 in the next year. This suggests a possible upside of 195.3% from the stock's current price. View Analyst Price Targets for Inovio Pharmaceuticals.

What is the consensus analysts' recommendation for Inovio Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inovio Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Inovio Pharmaceuticals.

What are Wall Street analysts saying about Inovio Pharmaceuticals stock?

Here are some recent quotes from research analysts about Inovio Pharmaceuticals stock:
  • 1. HC Wainwright analysts commented, "We are maintaining our Buy rating of EDAP TMS and our 12-month price target of $6.50 per diluted ADS. We derived our price target based on the average of two valuation methods: 1) price-earnings multiple using 25x 2026 EPS estimate discounted at 12%; and 2) discounted cash flow analysis using a 2% terminal growth rate and discounting 2026 free cash flow estimate at a 12% discount rate. (1) commercial; (2) regulatory; (3) currency; (4) reimbursement; and (5) intellectual property." (6/11/2019)
  • 2. According to Zacks Investment Research, "Inovio’s earnings and revenues missed estimates in the first quarter of 2019. The company’s progress with its lead pipeline candidate, VGX-3100, for the treatment of cervical dysplasia is encouraging. Apart from VGX-3100, Inovio also has some promising vaccine candidates in its portfolio, which are progressing well. Additionally, Inovio has collaboration with big pharma companies like Roche, Regeneron and AstraZeneca, which helps the company with their expertise for further growth. Moreover, the company’s targeted cervical cancer market holds untapped potential. However, the company has no approved product in its portfolio and its excessive dependence on its partners for funding the development of its pipeline candidates raises a concern. Shares have underperformed the industry year to date." (5/28/2019)
  • 3. Maxim Group analysts commented, "Inovio and its collaborators from The Wistar Institute presented positive preclinical data from its novel dBiTE (DNA-Encoded Bi-specific T Cell Engager) program at the American Association for Cancer Research (AACR) annual meeting." (4/3/2019)

Has Inovio Pharmaceuticals been receiving favorable news coverage?

Headlines about INO stock have trended very negative this week, InfoTrie reports. The research firm ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Inovio Pharmaceuticals earned a news impact score of -3.0 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Inovio Pharmaceuticals.

Are investors shorting Inovio Pharmaceuticals?

Inovio Pharmaceuticals saw a decrease in short interest during the month of October. As of October 31st, there was short interest totalling 11,090,000 shares, a decrease of 5.3% from the September 30th total of 11,710,000 shares. Based on an average daily trading volume, of 612,300 shares, the short-interest ratio is currently 18.1 days. Currently, 11.7% of the shares of the stock are short sold. View Inovio Pharmaceuticals' Current Options Chain.

Who are some of Inovio Pharmaceuticals' key competitors?

What other stocks do shareholders of Inovio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inovio Pharmaceuticals investors own include Anavex Life Sciences (AVXL), Sonoma Pharmaceuticals (SNOA), POET Technologies (POETF), WPX Energy (WPX), Opko Health (OPK), Synergy Pharmaceuticals (SGYP), Advanced Micro Devices (AMD), Micron Technology (MU), Novavax (NVAX) and Cara Therapeutics (CARA).

Who are Inovio Pharmaceuticals' key executives?

Inovio Pharmaceuticals' management team includes the folowing people:
  • Dr. J. Joseph Kim, CEO, Pres & Director (Age 50)
  • Mr. Peter D. Kies, Chief Financial Officer (Age 56)
  • Dr. Jacqueline E. Shea, COO & Exec. VP (Age 53)
  • Dr. Mark L. Bagarazzi, Chief Medical Officer (Age 58)
  • Dr. Laurent M. Humeau, Chief Scientific Officer & Exec. VP (Age 52)

Who are Inovio Pharmaceuticals' major shareholders?

Inovio Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (5.21%), Nikko Asset Management Americas Inc. (5.21%), Defender Capital LLC. (0.63%), SG Americas Securities LLC (0.07%), Tocqueville Asset Management L.P. (0.06%) and California Public Employees Retirement System (0.04%). Company insiders that own Inovio Pharmaceuticals stock include David B Weiner, Jong Joseph Kim, Laurent Humeau, Peter Kies and Simon X Benito. View Institutional Ownership Trends for Inovio Pharmaceuticals.

Which institutional investors are selling Inovio Pharmaceuticals stock?

INO stock was sold by a variety of institutional investors in the last quarter, including Defender Capital LLC., Tocqueville Asset Management L.P. and California Public Employees Retirement System. Company insiders that have sold Inovio Pharmaceuticals company stock in the last year include David B Weiner, Jong Joseph Kim and Peter Kies. View Insider Buying and Selling for Inovio Pharmaceuticals.

Which institutional investors are buying Inovio Pharmaceuticals stock?

INO stock was bought by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., SG Americas Securities LLC and Wedbush Securities Inc.. View Insider Buying and Selling for Inovio Pharmaceuticals.

How do I buy shares of Inovio Pharmaceuticals?

Shares of INO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Inovio Pharmaceuticals' stock price today?

One share of INO stock can currently be purchased for approximately $2.48.

How big of a company is Inovio Pharmaceuticals?

Inovio Pharmaceuticals has a market capitalization of $248.02 million and generates $30.48 million in revenue each year. The biopharmaceutical company earns $-96,970,000.00 in net income (profit) each year or ($1.05) on an earnings per share basis. Inovio Pharmaceuticals employs 281 workers across the globe.View Additional Information About Inovio Pharmaceuticals.

What is Inovio Pharmaceuticals' official website?

The official website for Inovio Pharmaceuticals is http://www.inovio.com/.

How can I contact Inovio Pharmaceuticals?

Inovio Pharmaceuticals' mailing address is 660 W. GERMANTOWN PIKE SUITE 110, PLYMOUTH MEETING PA, 19462. The biopharmaceutical company can be reached via phone at 267-440-4200 or via email at [email protected]


MarketBeat Community Rating for Inovio Pharmaceuticals (NASDAQ INO)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  567 (Vote Outperform)
Underperform Votes:  360 (Vote Underperform)
Total Votes:  927
MarketBeat's community ratings are surveys of what our community members think about Inovio Pharmaceuticals and other stocks. Vote "Outperform" if you believe INO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel